Jacobson Pharma's Fiscal H1 Profit Declines 9%

MT Newswires Live

Nov 21, 2024

Jacobson Pharma (HKG:2633) recorded a profit attributable to shareholders of HK$140.3 million for the six months ended Sept. 30, 8.9% lower than HK$154.0 million a year ago.

Earnings per share fell to HK$0.0707 from HK$0.0806 in the year-ago period.

The profit decline resulted from no longer consolidating the results of JBM Healthcare, a Thursday filing with the Hong Kong Exchange said.

The drugmaker's revenue was HK$810 million, up 13.3% from HK$714.9 million a year earlier.

The company attributed the higher revenue to the robust performance of its generic drug business and additional income from newly launched and newly in-licensed products.

The board recommended an interim dividend of HK$0.035 per share, compared to HK$0.025 per share last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2485851495"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485851495\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2485851495?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485851495","market":"fut","top_or_hot":-1,"title":"Jacobson Pharma's Fiscal H1 Profit Declines 9%","media":"MT Newswires Live","content":"<html><body><p> Jacobson Pharma (HKG:2633) recorded a profit attributable to shareholders of HK$140.3 million for the six months ended Sept. 30, 8.9% lower than HK$154.0 million a year ago.</p><p>Earnings per share fell to HK$0.0707 from HK$0.0806 in the year-ago period.</p><p>The profit decline resulted from no longer consolidating the results of JBM Healthcare,  a Thursday filing with the Hong Kong Exchange said.</p><p>The drugmaker's revenue was HK$810 million, up 13.3% from HK$714.9 million a year earlier.</p><p>The company attributed the higher revenue to the robust performance of its generic drug business and additional income from newly launched and newly in-licensed products.</p><p>The board recommended an interim dividend of HK$0.035 per share, compared to HK$0.025 per share last year.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jacobson Pharma's Fiscal H1 Profit Declines 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJacobson Pharma's Fiscal H1 Profit Declines 9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-21 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Jacobson Pharma (HKG:2633) recorded a profit attributable to shareholders of HK$140.3 million for the six months ended Sept. 30, 8.9% lower than HK$154.0 million a year ago.</p><p>Earnings per share fell to HK$0.0707 from HK$0.0806 in the year-ago period.</p><p>The profit decline resulted from no longer consolidating the results of JBM Healthcare,  a Thursday filing with the Hong Kong Exchange said.</p><p>The drugmaker's revenue was HK$810 million, up 13.3% from HK$714.9 million a year earlier.</p><p>The company attributed the higher revenue to the robust performance of its generic drug business and additional income from newly launched and newly in-licensed products.</p><p>The board recommended an interim dividend of HK$0.035 per share, compared to HK$0.025 per share last year.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02633","symbol_name":"雅各臣科研制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2485851495","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485851495","pubTimestamp":1732194134,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Jacobson Pharma  recorded a profit attributable to shareholders of HK$140.3 million for the six months ended Sept. 30, 8.9% lower than HK$154.0 million a year ago.Earnings per share fell to HK$0.0707 from HK$0.0806 in the year-ago period.The profit decline resulted from no longer consolidating the results of JBM Healthcare,  a Thursday filing with the Hong Kong Exchange said.The drugmaker's revenue was HK$810 million, up 13.3% from HK$714.9 million a year earlier.The company attributed the higher revenue to the robust performance of its generic drug business and additional income from newly launched and newly in-licensed products.The board recommended an interim dividend of HK$0.035 per share, compared to HK$0.025 per share last year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02633":"雅各臣科研制药","BK1191":"制药"},"translate_title":"雅各布森制药上半年利润下降9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02633":0.9},"content_text":"Jacobson Pharma (HKG:2633) recorded a profit attributable to shareholders of HK$140.3 million for the six months ended Sept. 30, 8.9% lower than HK$154.0 million a year ago.Earnings per share fell to HK$0.0707 from HK$0.0806 in the year-ago period.The profit decline resulted from no longer consolidating the results of JBM Healthcare,  a Thursday filing with the Hong Kong Exchange said.The drugmaker's revenue was HK$810 million, up 13.3% from HK$714.9 million a year earlier.The company attributed the higher revenue to the robust performance of its generic drug business and additional income from newly launched and newly in-licensed products.The board recommended an interim dividend of HK$0.035 per share, compared to HK$0.025 per share last year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}